IB001
Nerve Injury
Pre-clinicalActive
Key Facts
About Interactome Biotherapeutics
Interactome Biotherapeutics is a private, pre-clinical stage biotech leveraging a next-generation Secretome platform derived from progenitor cells and exosomes. The company's core technology, Nanovate™, aims to harness the complex signaling of extracellular vesicles and proteins to address significant unmet needs in nerve injury, rare diseases, and oncology. With a recently formed Scientific Advisory Board and an option agreement with Oxford University Innovation, Interactome is building its scientific and partnership foundation to advance its therapeutic pipeline.
View full company profile